Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the
one increases the prevalence and incidence and worsens the prognosis of the other. Their …

In real-world clinical practice, underdosing, ie off-label use of reduced doses (RDs), of oral
factor Xa inhibitors (oFXaIs) is quite common in stroke prevention in non-valvular atrial …

The approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial
fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Background The effectiveness and safety of dabigatran etexilate (DE) have not been
elucidated thoroughly in clinical practice for Japanese patients with non-valvular atrial …

The purpose of this study was to assess the association between reduced apixaban dose
and two outcomes: ischemic stroke/systemic embolism (SE) and major bleeding. We …

Non-vitamin K antagonist oral anticoagulants (NOACs) are commonly used in stroke
prevention in patients with atrial fibrillation. Although the rules for using standard and …

Background Rhythm-control strategy, including catheter ablation (CA) application,
constitutes an integral part of atrial fibrillation (AF) management. However, elderly patients …

Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in
numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from …

This study aims to provide real-world data about starting-dose of NOACs and dose-
adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation …